Journal Watch · ACS Nano · 2026

Nicotinamide-Loaded Peptoid Nanotubes for Energy Regeneration in Acute Brain Injury.

In the neonatal brain injury field, this work demonstrates the development of an innovative nanoparticle platform from first-principles design and synthesis to <i>in vitro</i> screening and then demonstration of efficacy <i>in vivo</i>.

Du H, Trinh TKH, Brandon OC et al.ACS Nano3 min readPharma relevance 65/100

DOI: 10.1021/acsnano.5c19897PMID: 41973499Study type: in-vitro / cell study

TL;DR

In the neonatal brain injury field, this work demonstrates the development of an innovative nanoparticle platform from first-principles design and synthesis to <i>in vitro</i> screening and then demonstration of efficacy <i>in vivo</i>.

Key findings

  • A single systemic dose of NAM-PNTs localized in microglia in the injured hemisphere and reduced brain tissue loss and improved neuropathology after hypoxia-ischemia in term-equivalent rats.
  • These findings highlight the therapeutic potential of NAM-PNTs for cell-specific targeted delivery and energy restoration in the acutely injured neonatal brain.
  • In the neonatal brain injury field, this work demonstrates the development of an innovative nanoparticle platform from first-principles design and synthesis to <i>in vitro</i> screening and then demonstration of efficacy <i>in vivo</i>.

What they did

By self-assembling peptoids into tubular structures, we created biocompatible NAM-conjugated peptoid nanotubes (NAM-PNTs) that vary in tubular length. NAM-PNTs demonstrated significant therapeutic benefits by enhancing cell viability and replenishing intracellular ATP levels within 24 h of treatment in oxygen-glucose-deprived (OGD) BV-2 cells. In organotypic brain slices, NAM-PNT treatment promoted glial proliferation, reduced proinflammatory cytokines, and increased anti-inflammatory cytokines after OGD, an <i>ex vivo</i> model of hypoxia-ischemia. The effect of NAM-PNTs is associated with their uptake into microglia via fluid-phase phagocytosis and caveolae-mediated endocytosis.

Full abstract (original)

Background: Acute brain injuries such as perinatal asphyxia, stroke, and traumatic brain injury result in ischemia, oxidative stress, excitotoxicity, and inflammation, leading to a depletion of ATP. Nicotinamide adenine dinucleotide (NAD+) is crucial for ATP regeneration and DNA repair during postinjury recovery. However, the therapeutic benefits of NAD+ and its precursors, such as nicotinamide (NAM), are limited by challenges in achieving effective cell-specific intracellular delivery. In this study, we use a nanopeptoid delivery strategy to replenish the cellular redox state and increase energy production in the acutely injured brain.

What they did: By self-assembling peptoids into tubular structures, we created biocompatible NAM-conjugated peptoid nanotubes (NAM-PNTs) that vary in tubular length. NAM-PNTs demonstrated significant therapeutic benefits by enhancing cell viability and replenishing intracellular ATP levels within 24 h of treatment in oxygen-glucose-deprived (OGD) BV-2 cells. In organotypic brain slices, NAM-PNT treatment promoted glial proliferation, reduced proinflammatory cytokines, and increased anti-inflammatory cytokines after OGD, an <i>ex vivo</i> model of hypoxia-ischemia. The effect of NAM-PNTs is associated with their uptake into microglia via fluid-phase phagocytosis and caveolae-mediated endocytosis.

Results & conclusions: A single systemic dose of NAM-PNTs localized in microglia in the injured hemisphere and reduced brain tissue loss and improved neuropathology after hypoxia-ischemia in term-equivalent rats. These findings highlight the therapeutic potential of NAM-PNTs for cell-specific targeted delivery and energy restoration in the acutely injured neonatal brain. In the neonatal brain injury field, this work demonstrates the development of an innovative nanoparticle platform from first-principles design and synthesis to <i>in vitro</i> screening and then demonstration of efficacy <i>in vivo</i>.

Abstract © the authors / ACS Nano (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acsnano.5c19897 · PubMed 41973499.

Why it matters for pharma & biotech

  • Relevant to Biotechnology & Methods teams tracking ACS Nano for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this ACS Nano study find?

In the neonatal brain injury field, this work demonstrates the development of an innovative nanoparticle platform from first-principles design and synthesis to <i>in vitro</i> screening and then demonstration of efficacy <i>in vivo</i>.

What type of study is this?

It is a in-vitro / cell study, published in ACS Nano in 2026. By self-assembling peptoids into tubular structures, we created biocompatible NAM-conjugated peptoid nanotubes (NAM-PNTs) that vary in tubular length.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acsnano.5c19897. PubMed ID: 41973499. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Du H, Trinh TKH, Brandon OC et al.. Nicotinamide-Loaded Peptoid Nanotubes for Energy Regeneration in Acute Brain Injury.. ACS Nano (2026). DOI: 10.1021/acsnano.5c19897.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/nicotinamide-loaded-peptoid-nanotubes-for-energy-regeneration-in-acute-b-c19897/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides